Pharmaxis Prioritises Breakthrough Clinical Program on Myelofibrosis
Release Date: 02/11/2020 8:30am
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced details of the clinical development plan for its lead drug pipeline asset being studied for the bone marrow cancer myelofibrosis.
PXS-5505 has already received IND approval and Orphan Drug Designation from the FDA and will proceed to an open label study recruiting up to 42 patients with myelofibrosis in Australia and international sites. PXS-5505 is a pan-LOX inhibitor that seeks to reverse the bone marrow fibrosis that drives morbidity and mortality in the disease.
Categories: News and Media